Amcenestrant did not improve outcomes over letrozole in patients with ER-positive, HER2-negative advanced breast cancer receiving palbociclib.

The combination of mitazalimab and mFOLFIRINOX appears effective for patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

A landmark Supreme Court decision that reins in federal agencies’ authority is expected to have dramatic consequences for the nation’s health care system.

The Supreme Court’s decision overturned Chevron U.S.A. v. Natural Resources Defense Council, which held that courts should generally back a federal agency’s statutory interpretation as long as it is ...

(HealthDay News) — Precision-guided treatment can improve outcomes of high-risk pediatric cancers, according to a study published in Nature Medicine. To examine which patients would benefit most from ...

Co-design refers to collaborations between researchers and stakeholders in the development of interventions, resources, and programs.

R0 resection is less prognostic in patients with low-grade serous ovarian cancer than in patients with other types of ovarian cancer.

This article reviews recent clinician crime activity related to the unlawful dispensing and distribution of prescription medications.

Phase 2 data suggest that perioperative treatment with mFOLFIRINOX may be safe and effective for patients with pancreatic cancer.

Survey results suggest there are few barriers to biosimilar use in community oncology practices in the United States.

Patients with early-stage cervical cancer have worse outcomes with minimally invasive surgery than with open radical hysterectomy, data suggest.

The median progression-free survival from first randomization was 83.7 months in the daratumumab-VTd arm and 52.8 months in the VTd arm. Adding daratumumab to treatment with bortezomib, thalidomide, ...